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When  threatened  by pathogenic  organisms  or neoplastic  disease,  the  mam- 
malian  host responds with a  complex repertoire  of metabolic alterations  (1-3). 
During  acute infection,  accelerated  protein and  lipid catabolism are  often ob- 
served, as are fever, hypoglycemia, and shock. In chronic neoplastic or infectious 
disease states,  unabated  depletion  of energy  stores  may lead  to cachexia,  and 
ultimately, to the demise of the host. These processes appear to be governed by 
the immune system, which, in part, exerts its influence over other somatic tissues 
through the action of various cytokines. 
Recently  (4),  we reported  the  isolation  of cachectin,  a  murine  macrophage 
hormone  capable of suppressing  the  expression  of anabolic enzymes in adipo- 
cytes,  thus  preventing  the  uptake  and  storage  of triglyceride.  Subsequently, 
cachectin  was  shown  (5)  to  be  identical  to  tumor  necrosis  factor  (TNF),  a 
monokine known for its ability to selectively lyse malignantly transformed cells 
(6-8). Although this latter property has been the most studied, we have suggested 
that  the biological function of this monokine is far broader.  Cachectin/TNF  is 
secreted in large quantities by endotoxin-induced macrophages, or macrophage- 
derived cells (4, 9).  Upon interaction with a specific plasma membrane receptor 
on the adipocyte (4),  it is capable of altering  cellular metabolism by selectively 
suppressing  the  expression of mRNA encoding specific anabolic  proteins (10). 
Cachectin/TNF  has been implicated both as the primary mediator of shock in 
the  setting  of gram-negative  septicemia  (1 1),  and  as the agent  responsible  for 
cachexia in chronic infectious disease states (12). Thus,  it seems that  cachectin 
plays  a  major  role  in  the  mammalian  inflammatory  response.  As  such,  it  is 
functionally related to several other inflammatory cytokines, including the inter- 
ferons (IFN), interleukins (IL), and granulocyte-macrophage colony stimulating 
factors. 
Inflammation  depends,  in  part,  upon regional  production  of proteolytic en- 
zymes  that  participate  in  the  destruction  and  remodelling  of tissues.  It  has 
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previously been shown that IL-1  elicits coilagenase secretion and prostaglandin 
E2 (PGE2) synthesis by human synovial cells (13-15) and dermal fibroblasts (15). 
Collagenase acts to disrupt the extracellular collagen matrix in inflamed tissues 
(16).  PGE2  is  believed  to  be  an  important  stimulus  for  the  production  of 
intracellular proteases (17,  18), and is also known to trigger bone resorption by 
osteoclasts in the course of inflammatory disease (19).  Herein, we observe that 
cachectin/TNF also evokes the production of collagenase and PGE2 by synovial 
cells and dermal fibroblasts. 
Materials and Methods 
Purified mouse cachectin/TNF was prepared as previously described (5). In the prep- 
arations used for these experiments, IL-I (leukocyte activating factor [LAF]) activity was 
assayed (14) and found to be absent.  Human mononuclear cell factor (MCF/IL-1) was 
isolated by the method of Dayer et al. (20), and was free of IL-2 and IFN-'r activities. 
LAF activity was measured in this preparation as previously described (14).  Human IFN- 
a was obtained from Hoffmann-La Roche, Inc. (Basel, Switzerland). Homogeneously pure 
mouse recombinant (r) 1L-1 was obtained from P. Lomedico of Hoffmann-La Roche, Inc. 
Lipopolysaccharide (LPS) (E.  coli strain 055:B5) was obtained from Difco Laboratories 
(Detroit, MI). 
Human synovial cells were isolated by proteolytic dispersion (13) from surgical synov- 
ectomy specimens,  obtained  from  patients  with  rheumatoid  arthritis.  Cultures  were 
established and cells were passaged by methods detailed previously (15).  The adherent 
synovial cells (ASC) obtained from the primary cultures were plated in 96-well flat-bottom 
plates  (Costar,  Cambridge,  MA)  at  a  density of 2  X  104  cells/well,  using  Dulbecco's 
modified Eagle's medium (DMEM) supplemented with  10% fetal bovine serum  (FBS). 
ASC were used as targets for the action of the above mediators 3-6 d after plating. For 
assay  of collagenase and  PGE2 production, the cells  were incubated in  DMEM supple- 
mented with  10% FBS, as well as 5 ~g/ml polymixin B (Sigma Chemical Co., St. Louis, 
MO) (polymixin B was omitted from wells used for the assay of LPS bioactivity). Cytokines 
were added to the final concentrations indicated. After 3 d, the medium was harvested, 
and determinations of collagenase and PGE~ levels were made. 
Human foreskin fibroblasts were similarly isolated from tissue specimens by protease 
treatment (13), and plated at near-confluence (2 X 104 cells in 200 ~,1 medium) in 96-well 
plates (Costar) using DMEM supplemented with  10%  FBS.  After 48 h of culture, fresh 
medium containing cytokines to be tested for collagenase or PGE2 induction was added 
to the culture. 
Collagenase activity was assayed as previously described (15) using [~4C]acetylated rat 
tail collagen as a substrate.  PGE~ was measured in culture media by radioimmunoassay 
using an antibody obtained from L. Levine (Brandeis University, Waltham, MA). 
All bioassays were performed in triplicate. 
Results and Discussion 
Addition of purified mouse cachectin/TNF to cultures of human synovial cells 
stimulated collagenase and PGE2 production in a dose-related manner (Table I). 
Significant stimulation  of both collagenase and  PGE2 production was apparent 
when cachectin/TNF concentrations exceeded 0.3 riM. The rise in both activities 
occurred in a parallel fashion over the range of concentrations tested. A saturat- 
ing concentration of cachectin/TNF (e.g.,  that  concentration required  to pro- 
duce maximal effects) was  not reached in the experiments performed.  Murine 
rIL-1  and  highly purified human  MCF/IL-1  also  elicited a  rise in  collagenase 
and  PGE2  production,  but  it  appeared  that  higher  concentrations  of  these DAYER  ET  AL.  BRIEF  DEFINITIVE  REPORT  2165 
TABLE  I 
Effect  of  Cachectin/TNF and Other  Mediators on PGE2 and 
Collagenase  Production by  Human Synovial  Cells 
Cytokine  PGE,  Collagenase  * 
gg/ml  U/ml 
Control  17 --- 6  <0.01 
LPS 5 #g/ml  16 --, 2  <0.01 
Cachectin/TNF (riM) 
0.03  27 "4" 5  <0.01 
0.3  87 --+ 12  0.21 +  0.03 
1.5  494 --. 36  0.25 ±  0.06 
3.0  650 +  49  0.46 _+ 0.08 
Mouse rlL-I 20 nM*  503 4- 45  0.15 -4- 0.02 
MCF/IL-I 5 nM*  772 4- 28  0.30 4- 0.05 
rlFN-a (U/ml) 
10  37 --. 3  <0.01 
100  26 --- 12  <0.01 
1,000  29 --- 10  <0.01 
* Mean --. SEM. 
* Molar concentration of IL-1 is based on the specific activity estimate of Lomedico 
et al. (26): 6 ×  105 U/mg (LAF assay). 
proteins were required to produce a response of the magnitude observed using 
cachectin/TNF. For example, a 20 nM concentration of rIL-1 (250 LAF U/ml) 
was necessary to promote stimulation comparable to that observed using 1.5 nM 
cachectin/TNF. 
rIFN-a  caused  no  demonstrable  increase  in  collagenase activity,  and  only 
slightly stimulated the production of PGE2.  The addition of LPS alone to the 
cultures, in the absence of polymixin B, did not stimulate either collagenase or 
PGE2 production. 
Dermal fibroblasts (Table II) were also stimulated by cachectin/TNF to pro- 
duce collagenase and PGE2.  In these experiments, dermal fibroblasts appeared 
relatively less sensitive to cachectin/TNF and relatively more sensitive to IL-1. 
Neither IFN-o~ nor LPS had a significant effect on collagenase or PGE2 produc- 
tion. 
Previous studies (13, 14, 16, 20) have implicated IL- 1 as the principal mediator 
for the induction of the proteolysis noted in rheumatoid arthritis and in other 
inflammatory  joint diseases. The enhanced secretion of collagenase and PGE2 by 
synovial cells are believed to contribute to the destructive process that is clinically 
observed. From the data presented above, however, it is apparent that cachec- 
tin/TNF, a  structurally distinct monokine, is a  very potent stimulator of colla- 
genase and  PGE2  production  by  synovial cells.  Moreover,  cachectin/TNF  is, 
under some circumstances, produced in far larger quantities than IL-1  in vivo. 
In  rabbits,  data  suggest  (21,  22)  that  several  milligrams  are  produced  per 
kilogram body mass in response to intravenous injection of LPS. 
The effect of cachectin/TNF on dermal fibroblasts is particularly interesting 
in view of the large quantities of the hormone that are bound by skin following 
injection  of the radiolabeled  hormone into  mice (21).  While  the role  of the 2166  DAYER ET  AL.  BRIEF  DEFINITIVE REPORT 
TABLE II 
Effect of Cachectin and Other Mediators on PGE2 and Collagenase 
Production by Human Dermal Fibroblasts 
Cytokine  PGE2  Collagenase 
~g/ml  U/ml 
Control  5  ---  1  <0.01 
LPS 5  t~g/ml  6  -  2  <0.01 
Cachectin/TNF  (riM) 
0.03  6  ---  1  <0.01 
0.3  15 +  3  <0.01 
1.5  27 +  5  <0.01 
3.0  54 +  3  0.11  +  0.02 
Mouse rIL-1  20 nM  105  +  17  0.36+  0.05 
MCF/IL-1  5  nM  109 --- 29  0.27  -+ 0.06 
rl FN-ot (U/ml) 
10  6  +  2  <0.01 
100  3  +  2  <0.01 
1,000  2  -+ 2  <0.01 
Concentration  values reported  as in Table I. 
hormone  in skin is unclear,  it may evoke some of the changes observed in this 
organ  in  response  to  infection,  e.g.,  vasoconstriction  and  increased  capillary 
fragility. The fact that keratinocytes are known to produce an IL-l-like substance 
(23) raises the question of whether they, like macrophages, are a potential source 
of cachectin/TN F. 
The  different  sensitivities of synovial cells and  dermal  fibroblasts to cachec- 
tin/TNF and  IL-1  indicate that cachectin/TNF  may exert a dominant effect in 
some tissues, whereas IL-1  may exert a  dominant  effect in others.  In addition, 
although IL-1 and cachectin/TNF are both produced by mononuclear phagocytic 
cells, the nature of the stimuli that evoke production of IL-1 differ substantially 
from  those  that  evoke  production  of cachectin/TNF.  For  example,  IL-1  is 
produced in comparable amounts, whether induced by T  lymphocyte products, 
LPS, concanavalin A, or phorbol ester (24), whereas cachectin/TNF production 
is induced  far more strongly by LPS than  by concanavalin  A  or phorboi  ester 
(25).  Thus,  the  selective inducibility  of these two monokines,  and  the  graded 
sensitivity  of their  target  tissues,  may  allow  for  the  broad  variability  of the 
biological effects that occur when different invasive agents challenge the integrity 
of the host. 
It is important to note that cachectin/TNF is capable of binding via a specific 
receptor to a  wide range of tissues (4,  21), with biological effects that  have yet 
to be determined. Given its potency in eliciting collagenase and PGE~ production 
by human  synovial cells,  cachectin/TNF  (rather  than  IL-1) may represent  the 
major  mediator  of  this  phenomenon  in  vivo.  Similarly,  many  of  the  other 
bioactivities  once  thought  to  be  mediated  exclusively  by  IL-1  (e.g.,  muscle 
proteolysis,  bone  resorption,  fever)  might  actually  be  attributable  to  cachec- 
tin/TNF.  A careful reappraisal of these activities seems appropriate. DAYER ET  AL.  BRIEF  DEFINITIVE REPORT  2167 
Summary 
Cachectin/TNF  (tumor  necrosis  factor),  an  endotoxin-induced  murine  mac- 
rophage hormone implicated in the pathogenesis of cachexia and shock, has been 
found capable of stimulating collagenase and prostaglandin E2 (PGE2) production 
by isolated human synovial cells and dermal fibroblasts. This bioactivity associated 
with cachectin  is comparable to that observed with the  monokine interleukin  1 
(IL-1), previously suggested as the major mediator of proteolysis. The ability of 
cachectin/TNF  to  stimulate  collagenase  and  PGE2  production  suggests  that  it 
may play a  role in tissue destruction  and  remodelling,  as these processes occur 
in inflammatory diseases. 
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